Moleculin Biotech (NASDAQ:MBRX) Receives Buy Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of Moleculin Biotech (NASDAQ:MBRX) in a report issued on Tuesday,Benzinga reports. The firm currently has a $22.00 price target on the stock.

MBRX has been the subject of a number of other reports. Weiss Ratings reissued a “sell (e+)” rating on shares of Moleculin Biotech in a research note on Thursday, January 22nd. Roth Mkm reissued a “buy” rating on shares of Moleculin Biotech in a research report on Monday, December 15th. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $22.00.

Moleculin Biotech Price Performance

Shares of NASDAQ MBRX opened at $2.25 on Tuesday. Moleculin Biotech has a 1 year low of $1.79 and a 1 year high of $33.00. The firm has a 50-day simple moving average of $3.33 and a two-hundred day simple moving average of $6.94. The company has a market cap of $4.59 million, a P/E ratio of -0.07 and a beta of 1.73.

Hedge Funds Weigh In On Moleculin Biotech

An institutional investor recently bought a new position in Moleculin Biotech stock. Jane Street Group LLC purchased a new stake in shares of Moleculin Biotech, Inc. (NASDAQ:MBRX) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 22,550 shares of the company’s stock, valued at approximately $75,000. Jane Street Group LLC owned about 1.11% of Moleculin Biotech as of its most recent filing with the Securities & Exchange Commission. 15.52% of the stock is owned by institutional investors and hedge funds.

Moleculin Biotech Company Profile

Moleculin Biotech, Inc is a clinical-stage pharmaceutical company focused on the development of novel therapies for the treatment of highly resistant tumors and viral infections. The company’s research platform centers on the design and synthesis of drug candidates that target key cellular pathways in cancer cells and viral replication processes. By leveraging a proprietary chemistry approach, Moleculin aims to address diseases that have limited therapeutic options and high unmet medical need.

The company’s pipeline includes multiple product candidates at various stages of development.